[Form 4] AC Immune SA Insider Trading Activity

Rhea-AI Filing Summary

AC Immune SA director June Carl Howard reported new equity compensation grants. On June 11, 2026, she received 16,568 common shares as a restricted share unit grant under the AC Immune SA 2016 Stock Option and Incentive Plan.

Following this award, her direct holdings in common shares were 67,556. She also received share options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036. These awards reflect compensation rather than open‑market trading.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider June Carl Howard

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	38,889	$0.00	--
Grant/Award	Common Share	16,568	$0.00	--

Holdings After Transaction: Share Option (right to buy) — 38,889 shares (Direct, null); Common Share — 67,556 shares (Direct, null)

Footnotes (1)

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Includes 66,556 common shares underlying outstanding restricted share units. On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

June Carl Howard

(Last) (First) (Middle)

409 BAIRD RD

(Street)

MERION PENNSYLVANIA 19066

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Share	06/11/2026		A		16,568	A	$0(1)	67,556(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.62	06/11/2026		A		38,889		06/10/2027(3)	06/10/2036	Common Share	38,889	$0	38,889	D

Explanation of Responses:

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).

2. Includes 66,556 common shares underlying outstanding restricted share units.

3. On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.

	Matthias Maurer as Attorney-in-Fact for Carl June	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)